Inactive Instrument
BioSyent Inc. Stock Other OTC
Stocks
BIOYF
CA0906901081
Pharmaceuticals
OTC Markets Traded| Market Cap | 172M 123M 107M 99.93M 91.18M 11.75B 174M 1.17B 459M 5.88B 462M 452M 19.62B | P/E 2026 * |
16.9x | P/E 2027 * | 13.9x |
|---|---|---|---|---|---|
| Enterprise Value | 172M 123M 107M 99.93M 91.18M 11.75B 174M 1.17B 459M 5.88B 462M 452M 19.62B | EV / Sales 2026 * |
2.49x | EV / Sales 2027 * | 2.08x |
| Free-Float |
64.14% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioSyent Inc.
| 1 day | +0.67% |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
Peter Lockhard
BRD | Director/Board Member | 62 | 2002-05-31 |
Stephen Wilton
BRD | Director/Board Member | 65 | 2014-01-15 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.67% | -.--% | - | - | 123M | |
| -1.37% | +8.90% | +91.28% | +130.00% | 1,098B | |
| -0.77% | +1.91% | +49.46% | +49.44% | 631B | |
| +0.85% | +2.58% | +25.90% | +64.34% | 438B | |
| -1.13% | +3.13% | +49.78% | +39.13% | 368B | |
| -0.74% | +1.01% | +31.08% | +38.64% | 298B | |
| -1.22% | +0.89% | +7.32% | +7.38% | 251B | |
| -0.70% | +6.23% | +45.32% | +57.82% | 226B | |
| +0.34% | -0.13% | -4.77% | -50.50% | 209B | |
| +2.04% | +0.38% | +12.70% | +69.71% | 165B | |
| Average | -0.20% | +1,662.58% | +34.23% | +45.11% | 409.37B | |
| Weighted average by Cap. | -0.63% | +1,339.54% | +49.81% | +66.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 69M 49.53M 42.93M 40.19M 36.67M 4.72B 70.16M 471M 185M 2.36B 186M 182M 7.89B | 82.3M 59.08M 51.2M 47.93M 43.73M 5.64B 83.68M 562M 220M 2.82B 222M 217M 9.41B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
